SITC Resource Library

On March 30, 2021, leading experts in cancer immunotherapy discussed the latest advances in cancer immunotherapy emerging from The Society for Immunotherapy of Cancer's 35th Annual Meeting (SITC 2020). The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Moderator: Jason Luke, MD – University of Pittsburgh Medical Center
• Presenters:
  • Diwakar Davar, MD – University of Pittsburgh Medical Center
  • Karl Lewis, MD – University of Colorado
  • Ignacio Melero, MD, PhD – Fundación para la Investigación Médica Aplicada
  • Hussein Tawbi, MD, PhD – MD Anderson Cancer Center

• Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) – Presenter: Karl Lewis, MD
• First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumorso – Presenter: Ignacio Melero, MD, PhD
• Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results – Presenter: Diwakar Davar, MD
• Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce – Presenter: Hussein Tawbi, MD, PhD